SRR2016947
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.630
- MYC_TARGETS_V1+0.530
- E2F_TARGETS+0.470
- G2M_CHECKPOINT+0.430
- MTORC1_SIGNALING+0.360
- SPERMATOGENESIS+0.240
- OXIDATIVE_PHOSPHORYLATION+0.230
- CHOLESTEROL_HOMEOSTASIS+0.160
- MITOTIC_SPINDLE+0.150
- UNFOLDED_PROTEIN_RESPONSE+0.140
Top 10 suppressed
- COMPLEMENT-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- ALLOGRAFT_REJECTION-0.370
- MYOGENESIS-0.370
- INFLAMMATORY_RESPONSE-0.360
- INTERFERON_GAMMA_RESPONSE-0.360
- COAGULATION-0.350
- APOPTOSIS-0.320
- INTERFERON_ALPHA_RESPONSE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.911 |
| 2 | C3L-01285 | — | cohortSQ2 | 0.905 |
| 3 | TCGA-63-A5MI-01A-12R-A27Q-07 | — | cohortSQ1 | 0.903 |
| 4 | SRR650205 | — | — | 0.903 |
| 5 | BSR_04_0040_A3_S71 | — | B | 0.902 |
| 6 | SRR6013537 | — | cohortA3 | 0.896 |
| 7 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.895 |
| 8 | MNG531 | — | — | 0.892 |
| 9 | BS_YETBN0RQ | medulloblastoma | — | 0.892 |
| 10 | SRR8518295 | — | E | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |